Results 51 to 60 of about 19,188,680 (306)

Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial

BMC Medicine, 2018
Background For patients starting treatment for depression, current guidelines recommend titrating the antidepressant dosage to the maximum of the licenced range if tolerated.
Tadashi Kato, Toshi A. Furukawa, Akio Mantani, Ken’ichi Kurata, Hajime Kubouchi, Susumu Hirota, Hirotoshi Sato, Kazuyuki Sugishita, Bun Chino, Kahori Itoh, Yoshio Ikeda, Yoshihiro Shinagawa, Masaki Kondo, Yasumasa Okamoto, Hirokazu Fujita, Motomu Suga, Shingo Yasumoto, Naohisa Tsujino, Takeshi Inoue, Noboru Fujise, Tatsuo Akechi, Mitsuhiko Yamada, Shinji Shimodera, Norio Watanabe, Masatoshi Inagaki, Kazuhira Miki, Yusuke Ogawa, Nozomi Takeshima, Yu Hayasaka, Aran Tajika, Kiyomi Shinohara, Naohiro Yonemoto, Shiro Tanaka, Qi Zhou, Gordon H. Guyatt, for the SUN☺D Investigators   +35 more
doaj   +1 more source

“We Cannot Talk as a Family”: Complexities of Survivorship Communication Among Hispanic/Latino Young Adult Survivors of Childhood Cancer, Parents, and Clinicians

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Young adult childhood cancer survivors (YA‐CCS) have an increased risk of treatment‐related health complications throughout their lives. Lifelong survivorship care is recommended, yet many YA‐CCS experience disruptions in care during pediatric‐to‐adult transitions and do not receive recommended survivorship care.
Kevin Shanchen Pu, Nicole Fernández‐Viña, Briana C. Martin‐Villa, Daniela Ramirez, Rebecca M. Lewinsohn, Mary Smith, Heidi Boynton, Lidia Schapira, Stephanie M. Smith   +8 more
wiley   +1 more source

Frequency of first- and second-line treatment.

, 2019
Frequency of first- and second-line treatment.
Thirupathi Pattipaka (6175754), Yulin Li (36434), Adrian Cassidy (6175760), Apar Kishor Ganti (6175763), Anita Appius (6175751), Andrea Feyereislova (6175757)   +5 more
core   +1 more source

Classical Complement Pathway Inhibition in a Pediatric Patient With Refractory Immune Thrombocytopenia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric refractory immune thrombocytopenia (rITP) is generally characterized by persistent thrombocytopenia and failure to achieve a sustained response to multiple standard therapies. We report a 4‐year‐old female with congenital tufting enteropathy, post‐intestinal transplant patient on immunosuppressants, who developed severe rITP ...
Sarah Hsieh, Susmita Sarangi, Caileigh Pudela, Catherine M. Broome, Tara K. Suntum   +4 more
wiley   +1 more source

Capecitabine as second-line treatment for metastatic cholangiocarcinoma: A report of two cases [PDF]

, 2002
Background: The management of recurrent, metastatic cholangiocarcinoma still remains a problem since this tumor entity is classified as chemotherapy-resistant.
Schalhorn, A., Stemmler, Joachim, Heinemann, Volker   +2 more
core   +1 more source

Evidence‐Based Clinical Practice Guidelines for the Management of Pediatric Febrile Neutropenia: Resource‐Sensitive Recommendations for the Asian Continent

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Febrile neutropenia (FN) is a frequent and serious complication in children receiving cancer therapy. Standardizing FN management across Asia is challenging due to variable healthcare infrastructure, diagnostic capacity, and infection patterns; however, it could improve resource use and patient outcomes.
Joliza Patricia Cañeba, Shweta Bansal, Tea Reljic, Allyne Montecillo‐Aguelo, Hamidah Alias, Farrah Amaranto, Maria Stella Aquino‐Calingasan, Bambang Ardianto, Eggi Arguni, Sally Blair, Thi Tam Dang, Maria Beatriz Gepte, Samanmalee Gunasekara, Andini Handayani, Miriam Kimpo, Catherine G. Lam, Nawachai Lertvivatpong, Sergio Licona, Ana Loseo, Ratha Mlis, Vivian Moreno Berrio, Nguyen Hoai Anh, Anna Lisa Ong‐Lim, Ha Thu Pham, Krishna Sagar Sharma, Bun Sereyleak, Sally Jane G. Velasco‐Aro, Su Yadana, Ambuj Kumar, Sheena Mukkada   +29 more
wiley   +1 more source

A systematic review and meta-analysis on utilizing anti-CD19 chimeric antigen receptor T-cell therapy as a second-line treatment for relapsed and refractory diffuse large B-cell lymphoma

Frontiers in Oncology
IntroductionInconsistent results observed in recent phase III trials assessing chimeric antigenic receptor T (CAR-T) cell therapy as a second-line treatment compared to standard of care (SOC) in patients with relapsed/refractory diffuse large B-cell ...
Kanwal Asghar, Maryam Zafar, Eva Holland, Ali Bin Abduljabbar, Sara A. Albagoush, Noureen Asghar, Akshat Sood, Jalal M. Dufani, Joseph Thirumalaredy, Bradley DeVrieze, Abubakar Tauseef, Muhammad Husnain   +11 more
doaj   +1 more source

Cervical cancer recurrence treatment (Second-line therapy).

, 2019
Cervical cancer recurrence treatment (Second-line therapy).
Magdalena Piróg (6281519), Lubomir Bodnar (6281510), Dorota Babczyk (6281516), Tomasz Basta (6281501), Robert Jach (6281531), Anna Horbaczewska (6281528), Paweł Knapp (6281504), Iwona Gawron (6281513), Paweł Blecharz (6281507), Anna Markowska (6281525), Tomasz Kluz (6281522)   +10 more
core   +1 more source

Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. [PDF]

, 2011
In resource-limited settings, many patients, with no prior protease inhibitor (PI) treatment on a second-line, high genetic barrier, ritonavir-boosted PI-containing regimen have virologic ...
Monica Gandhi, Yong Huang, McIlleron, Helen, Huang, Yong, Nachega, Jean B, van Mens, Thijs E, Malavazzi, Carolina, Thijs E van Mens, Helen McIlleron, Gert Uves van Zyl, Peter Smith, Eric Decloedt, Maartens, Gary, Gary Maartens, Decloedt, Eric, Gandhi, Monica, van Zyl, Gert Uves, Smith, Peter, Zeier, Michele, Lize van der Merwe, Michele Zeier, Carolina Malavazzi, Jean B Nachega, van der Merwe, Lize   +23 more
core   +1 more source

Impact of Initial Treatment Setting on Survival in Relapsed Pediatric and AYA Bone Sarcomas: A Secondary Analysis of a Prospective Clinical Trial

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Outcomes in relapsed or refractory pediatric and AYA bone sarcomas remain poor, and the impact of early referral to specialized sarcoma centers on survival is unclear. Early centralization of care may improve local and systemic treatment quality, but evidence in this population is limited.
Justyna Antoniuk‐Majchrzak, Katarzyna Bilska, Tomasz Koziński, Jadwiga Węcławek‐Tompol, Dorota Sega‐Pondel, Radosław Chaber, Wanda Badowska, Katarzyna Rosłan, Hanna Koseła‐Paterczyk, Anna Raciborska   +9 more
wiley   +1 more source